Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 287

1.

Optical Coherence Tomography and neurodegeneration: are eyes the windows to the brain?

Gupta S, Zivadinov R, Ramanathan M, Weinstock-Guttman B.

Expert Rev Neurother. 2016 May 3. [Epub ahead of print]

PMID:
27138997
2.

Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine.

Zivadinov R, Jakimovski D, Gandhi S, Ahmed R, Dwyer MG, Horakova D, Weinstock-Guttman B, Benedict RR, Vaneckova M, Barnett M, Bergsland N.

Expert Rev Neurother. 2016 Apr 22. [Epub ahead of print]

PMID:
27105209
3.

A case-control study of dietary salt intake in pediatric-onset multiple sclerosis.

McDonald J, Graves J, Waldman A, Lotze T, Schreiner T, Belman A, Greenberg B, Weinstock-Guttman B, Aaen G, Tillema JM, Hart J, Lulu S, Ness J, Harris Y, Rubin J, Candee M, Krupp LB, Gorman M, Benson L, Rodriguez M, Chitnis T, Mar S, Barcellos LF, Laraia B, Rose J, Roalstad S, Simmons T, Casper TC, Waubant E.

Mult Scler Relat Disord. 2016 Mar;6:87-92. doi: 10.1016/j.msard.2016.02.011. Epub 2016 Feb 12.

PMID:
27063630
4.

Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years.

Zivadinov R, Hojnacki D, Bergsland N, Kennedy C, Hagemeier J, Melia R, Ramasamy DP, Durfee J, Carl E, Dwyer MG, Weinstock-Guttman B.

Eur J Neurol. 2016 Jun;23(6):1101-9. doi: 10.1111/ene.12992. Epub 2016 Mar 21.

PMID:
26998905
5.

Long-Term Neurocognitive, Psychosocial, and Magnetic Resonance Imaging Outcomes in Pediatric-Onset Acute Disseminated Encephalomyelitis.

Beatty C, Bowler RA, Farooq O, Dudeck L, Ramasamy D, Yeh EA, Zivadinov R, Weinstock-Guttman B, Parrish JB.

Pediatr Neurol. 2016 Apr;57:64-73. doi: 10.1016/j.pediatrneurol.2016.01.003. Epub 2016 Jan 7.

PMID:
26996404
6.

Dicer and microRNA expression in multiple sclerosis and response to interferon therapy.

Magner WJ, Weinstock-Guttman B, Rho M, Hojnacki D, Ghazi R, Ramanathan M, Tomasi TB.

J Neuroimmunol. 2016 Mar 15;292:68-78. doi: 10.1016/j.jneuroim.2016.01.009. Epub 2016 Jan 21.

PMID:
26943961
7.

Benchmarks of meaningful impairment on the MSFC and BICAMS.

Benedict RH, Drake AS, Irwin LN, Frndak SE, Kunker KA, Khan AL, Kordovski VM, Motl RW, Weinstock-Guttman B.

Mult Scler. 2016 Feb 26. pii: 1352458516633517. [Epub ahead of print]

PMID:
26920379
8.

Extended interval dosing of natalizumab in multiple sclerosis.

Zhovtis Ryerson L, Frohman TC, Foley J, Kister I, Weinstock-Guttman B, Tornatore C, Pandey K, Donnelly S, Pawate S, Bomprezzi R, Smith D, Kolb C, Qureshi S, Okuda D, Kalina J, Rimler Z, Green R, Monson N, Hoyt T, Bradshaw M, Fallon J, Chamot E, Bucello M, Beh S, Cutter G, Major E, Herbert J, Frohman EM.

J Neurol Neurosurg Psychiatry. 2016 Feb 25. pii: jnnp-2015-312940. doi: 10.1136/jnnp-2015-312940. [Epub ahead of print]

PMID:
26917698
9.

Aging and multiple sclerosis.

Sanai SA, Saini V, Benedict RH, Zivadinov R, Teter BE, Ramanathan M, Weinstock-Guttman B.

Mult Scler. 2016 Feb 19. pii: 1352458516634871. [Epub ahead of print] Review.

PMID:
26895718
10.

Autoimmune Comorbidities Are Associated with Brain Injury in Multiple Sclerosis.

Zivadinov R, Raj B, Ramanathan M, Teter B, Durfee J, Dwyer MG, Bergsland N, Kolb C, Hojnacki D, Benedict RH, Weinstock-Guttman B.

AJNR Am J Neuroradiol. 2016 Feb 18. [Epub ahead of print]

PMID:
26892983
11.

Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis.

Roy S, Benedict RH, Drake AS, Weinstock-Guttman B.

CNS Drugs. 2016 Mar;30(3):209-25. doi: 10.1007/s40263-016-0319-6.

PMID:
26884145
12.

Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation.

Weinstock-Guttman B, Hagemeier J, Kavak KS, Saini V, Patrick K, Ramasamy DP, Nadeem M, Carl E, Hojnacki D, Zivadinov R.

J Neurol Neurosurg Psychiatry. 2016 Jan 18. pii: jnnp-2015-312221. doi: 10.1136/jnnp-2015-312221. [Epub ahead of print]

PMID:
26780938
13.

Humoral response to EBV is associated with cortical atrophy and lesion burden in patients with MS.

Zivadinov R, Cerza N, Hagemeier J, Carl E, Badgett D, Ramasamy DP, Weinstock-Guttman B, Ramanathan M.

Neurol Neuroimmunol Neuroinflamm. 2016 Jan 7;3(1):e190. doi: 10.1212/NXI.0000000000000190. eCollection 2016 Feb.

14.

Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report.

Chitnis T, Ness J, Krupp L, Waubant E, Hunt T, Olsen CS, Rodriguez M, Lotze T, Gorman M, Benson L, Belman A, Weinstock-Guttman B, Aaen G, Graves J, Patterson M, Rose JW, Casper TC.

Neurology. 2016 Jan 19;86(3):245-52. doi: 10.1212/WNL.0000000000002283. Epub 2015 Dec 18.

15.

Immunologic and MRI markers of the therapeutic effect of IFN-β-1a in relapsing-remitting MS.

Tao Y, Zhang X, Zivadinov R, Dwyer MG, Kennedy C, Bergsland N, Ramasamy D, Durfee J, Hojnacki D, Hayward B, Dangond F, Weinstock-Guttman B, Markovic-Plese S.

Neurol Neuroimmunol Neuroinflamm. 2015 Nov 12;2(6):e176. doi: 10.1212/NXI.0000000000000176. eCollection 2015 Dec.

16.

Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial.

Dwyer MG, Zivadinov R, Tao Y, Zhang X, Kennedy C, Bergsland N, Ramasamy DP, Durfee J, Hojnacki D, Weinstock-Guttman B, Hayward B, Dangond F, Markovic-Plese S.

BMC Neurol. 2015 Nov 11;15:232. doi: 10.1186/s12883-015-0488-9.

17.

Localized atrophy of the thalamus and slowed cognitive processing speed in MS patients.

Bergsland N, Zivadinov R, Dwyer MG, Weinstock-Guttman B, Benedict RH.

Mult Scler. 2015 Nov 5. pii: 1352458515616204. [Epub ahead of print]

PMID:
26541795
18.

Increased contrast enhancing lesion activity in relapsing-remitting multiple sclerosis migraine patients.

Graziano E, Hagemeier J, Weinstock-Guttman B, Ramasamy DP, Zivadinov R.

Neuroimage Clin. 2015 Aug 1;9:110-6. doi: 10.1016/j.nicl.2015.07.013. eCollection 2015.

19.

Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later.

Uher T, Horakova D, Tyblova M, Zeman D, Krasulova E, Mrazova K, Seidl Z, Vaneckova M, Krasensky J, Weinstock-Guttman B, Ramanathan M, Havrdova E, Zivadinov R.

Mult Scler. 2015 Sep 11. pii: 1352458515601903. [Epub ahead of print]

PMID:
26362893
20.

Identifying employed multiple sclerosis patients at-risk for job loss: When do negative work events pose a threat?

Kordovski VM, Frndak SE, Fisher CS, Rodgers J, Weinstock-Guttman B, Benedict RH.

Mult Scler Relat Disord. 2015 Sep;4(5):409-13. doi: 10.1016/j.msard.2015.07.005. Epub 2015 Jul 8.

PMID:
26346789
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk